ORIGINAL ARTICLE

Discovery of small molecule Gaq/11 protein inhibitors against uveal melanoma

Yang Ge†, Jun-Jie Deng†, Jianzheng Zhu†, Lu Liu, Shumin Ouyang, Zhendong Song, Xiaolei Zhang*, Xiao-Feng Xiong*

National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, Guangdong Province Engineering Laboratory for Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

Received 4 February 2022; received in revised form 7 April 2022; accepted 24 April 2022

KEY WORDS
G proteins; Gaq/11 inhibitors; SARs; BRET; Uveal melanoma; Antitumor; Safety; Pharmacokinetics

Abstract Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies. The mutated Gaq/11 are perceived as oncogenic drivers in the vast majority of uveal melanoma (UM) cases, making directly targeting Gaq/11 to be a promising strategy for combating UM. Herein, we report the optimization of imidazopiperazine derivatives as Gaq/11 inhibitors, and identified GQ262 with improved Gaq/11 inhibitory activity and drug-like properties. GQ262 efficiently blocked UM cell proliferation and migration in vitro. Analysis of the apoptosis-related proteins, extracellular signal-regulated kinase (ERK), and yes-associated protein (YAP) demonstrated that GQ262 distinctly induced UM cells apoptosis and disrupted the downstream effectors by targeting Gaq/11 directly. Significantly, GQ262 showed outstanding antitumor efficacy in vivo with good safety at the testing dose. Collectively, our findings along with the favorable pharmacokinetics of GQ262 revealed that directly targeting Gaq/11 may be an efficient strategy against uveal melanoma.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Heterotrimeric G proteins are the families of guanine nucleotide-binding proteins. The involvement of G proteins in transmembrane signal transduction was first discovered approximately 40 years ago. Heterotrimeric G proteins consist of 3 non-identical subunits (α, β, and γ) in the order of diminishing mass. In mammals, 21 different Ga subunits encoded by 16 genes, 6 different Gβ subunits encoded by 5 genes, and 12 different Gγ subunits encoded by 12 genes have been identified. G proteins are characterized and categorized into Ga, Gai, Gaq/11, and Gal2/13 with regard to the sequence similarity of Ga subunits. The downstream effectors coupled to individual Ga subunits are also distinct: (i) Ga stimulates adenylyl cyclase (AC), which synthesizes the cAMP from ATP; (ii) Gai suppresses AC, which controls the intracellular cAMP levels; (iii) Gaq/11 activate phospholipase Cβ (PLCβ), which generates diacylglycerol (DAG) and inositol triphosphate (IP3); and (iv) Gal2/13, which are identified to directly interact with guanine nucleotide exchange factors (GEFs) for the GT-Pase Rho (RhoGEF) and induce the activation of Rho.

G proteins, which in general are perceived as molecular switches, mediate signal transduction connecting the hemiphalical G protein-coupled receptors (GPCRs) with various intracellular effectors. Different from the transmembrane GPCRs, G proteins are situated in cells. The processes of signal transduction are initiated by extracellular stimuli binding to GPCRs, which induce the conformational change of GPCRs and activate G proteins. Consequently, the G proteins cycle is triggered to further transmit the signals. The signaling cycle could be interrupted by the mutation or covalent modification of Ga subunits. Under certain circumstances, the intrinsic GTPase activity of Ga is blocked, which retains the Ga in a “switch-on” state and persistently activates the complicated downstream signaling networks.

Of note, Ga proteins are served as the crucial nodes on the canonical GPCRs/G proteins effectors axis, and involved in extensive human pathological and physiological processes. In 2010, mutated Gaq (encoded by GNAQ) and Ga11 (encoded by GNA11) were unveiled to be associated with uveal melanoma (UM) clinical trials. The mutated Gaq proteins impair the GTP hydrolysis and prolong the signaling activity. The hot spots of Gaq mutations flock around two residues, K129 and R183. Hence, Gaq/11 harboring Q209 or R183 mutations are recognized as oncogenic drivers in the vast majority of UM cases. Over the past decade, enormous efforts for UM treatment were devoted to regulate the complex downstream signaling of Gaq/11, including two key nodes MAPK and ERK. Unfortunately, targeting either of the nodes did not exhibit satisfied therapeutic outcome in UM clinical trials. A presumable explanation is that Gaq/11 could activate multiple and independent downstream signaling pathways, targeting a specific node could not achieve the optimal therapeutic results. Thus, directly targeting the constitutively activated Gaq/11 maybe represent one potential application to overcome UM.

Up to now, very few reported Gaq/11 inhibitors are shown in Fig. 1, including YM-254890 (1), FR900359 (2), BIM-46187 (3), and GQ127 (4). The cyclic depsipeptide YM-254890 (1) powerfully inhibits Gaq/11 with the IC50 value of 95 nmol/L on CHO cells that stably express the M1 muscarinic receptor. Analysis of the Gaq/11/YM-254890 crystal structure demonstrated that 1 blocks the GDP/GTP exchange through suppressing the GDP release, FR900359 (2), which possesses subtle structural differences with YM-254890, exhibits inhibitory potency to Gaq/11 in low nanomolar range (IC50 = 32 nmol/L) and shares the same mode of action (MOA) with 1. Although 3 and 4 showed exciting bioactivity, the development of these two compounds is immensely restricted due to the low abundance in nature and synthetic complexity. BIM-46187 (3) was reported as a small molecular Gaq/11 inhibitor in 2014. 3 permits the GDP exit but prevents GTP entry, which is the possible mechanism of how 3 inhibits Gaq/11. However, the large molecular weight and high toxicity of 3 complicate its development. Recently, our group performed structural optimization towards 3 with the purpose of improving the Gaq/11 inhibitory potency, simplifying the structure, and reducing the toxicity. The small molecule GQ127 (4) was obtained as an effective Gaq/11 inhibitor in vitro and in vivo without obvious toxicity, in comparison with 3. Nevertheless, the electron-rich primary amine within 4 might be the issue for metabolic and oxidative stability, the relatively short elimination half-life (t1/2 = 1.2 h) and unsatisfactory Gaq/11 inhibitory potency encouraged us to pursue new small molecules with improved inhibitory potency and drug-like properties.

In this study, we performed structural optimization on compound 4 and successfully obtained GQ262 which showed improved Gaq/11 inhibitory potency. Moreover, the antitumor efficacy and mechanism of GQ262 were explored. The obtained data served as solid evidences for the good antitumor activity of GQ262 both in vitro and in vivo.

2. Results and discussion

2.1. Synthetic design

In our previous study, we developed compound 4 as a new Gaq/11 inhibitor by the structural optimization of 3. However, the Gaq/11 inhibitory activity, antitumor efficacy, and druggability of 4 are not satisfied. To further develop novel and potent Gaq/11 inhibitors with good druggability, our optimization began with modifying the phenyl group of 4 (Fig. 2). Based on the application of bioisosterism in drug discovery, we utilized different aromatic heterocycles to replace the phenyl group. We also substituted the aromatic heterocycles with alkyls, cycloalkyls, and hetero-cycloalkyls to investigate the necessity of the rigid structure. When analyzing the structural characteristics of 4, we speculated that whether the flexibility of the amino acid fragment is related to the Gaq/11 inhibitory potency. Thus, the carbonyl group was reduced to increase the flexibility to explore the relationships between the flexibility and efficacy. In addition, the cyclohexylmethyl group was replaced by other alkyl groups to further investigate the structure—activity relationships (SARs), by combining with the results of augmenting efficacy in our studies.

Ultimately, GQ220–GQ267 were synthesized for further evaluation of inhibitory effects on Gaq/11 and UM cells.

2.2. Chemistry

GQ220–GQ235 were prepared according to the synthetic route depicted in Scheme 1. The synthesis of imidazopyrazine analogs began with the commercially available N-tert-butoxycarbonyl-l-cyclohexylalanine methyl ester 5 which was treated with sodium borohydride in tetrahydrofuran (THF)/methanol, followed by treating with Dess-Martin periodinane to give intermediate 6 in 75% yield. 7 was obtained from 6 by Debus–Radziszewski
reaction. Treating 7 with iodine and potassium hydroxide in N,N-dimethylformamide (DMF) gave 8. Then, nucleophilic substitution between 8 and ethyl bromoacetate was performed to deliver 9. Deprotection and intramolecular lactamization of 9 gave 10, followed by reducing the amide group by borohydride in methanol/THF resulted in 12. The key building blocks 13a–13p were prepared from 12 by Suzuki reaction. Finally, compounds GQ220–GQ235 were furnished by the condensation of N-tert-butoxycarbonyl-L-isoleucine with 13a–13p and removing the protecting groups.

The synthesis of imidazopyrazine analogs GQ236–GQ267 started from N-Boc-protected amino acids 15a–15e (Scheme 2). Treating 15a–15e with cesium carbonate in DMF containing 2-bromoacetophenone. Then, the mixtures were treated with ammonium acetate (NH₄OAc) to obtain 16a–16e. Treating 16a–16e with ethyl bromoacetate to obtain intermediates 17a–17e by the nucleophilic substitutions. Deprotection and intramolecular lactamization of 17a–17e were performed to prepare 18a–18e. Building blocks 19a–19e were furnished by reducing the amide groups. Successively, condensation of 19a–19e with amino acids, deprotection and reducing with borane delivered GQ236–GQ267. In total, 48 new imidazopyrazine derivatives were prepared.

### 2.3. Structure–activity relationship studies

Inositol monophosphate (IP₁) accumulation assay was utilized to characterize Gaq/11 inhibitory activity on CHO-M₁ cells, which applied homogeneous time-resolved fluorescence (HTRF). In vitro antiproliferative potency was evaluated on UM cell lines MP41 and GNA11Q209L mutation and 92.1 with GNAQQ209L mutation antiproliferative potency was evaluated on UM cell lines MP41 and 92.1 cell lines, suggesting that the aromatic substitution is essential for maintaining the activity. The amino acid fragment in 4 was proven to be essential for keeping the Gaq/11 inhibitory activity and reducing the cellular toxicity, we speculated whether increasing the molecular flexibility by reducing the amide group to tertiary amine could contribute to the inhibitory potency. Interestingly, reducing the amide group in 4 led to analog GQ236, which exhibited remarkable improvement both in inhibiting Gaq/11 and suppressing the proliferation of MP41 and 92.1 cells. The exciting results encouraged us to further explore the side chain of the amino acid part. Considering the natural and some unnatural amino acids with side chain diversity are abundant and easily available building blocks, we chose four natural and five unnatural amino acids with different alkyl branched chains and prepared GQ237–GQ245. As shown in Table 2, most compounds displayed improved Gaq/11 inhibitory activity at the concentration of 10 μmol/L in comparison to 3, except for GQ240 and GQ241. It is worth noting that the antiproliferative activity of these compounds on UM cells were also enhanced or maintained. Encouraged by these results, other natural amino acids with different side chains were employed to obtain GQ246–GQ259. Of note, all these compounds exhibited favorable Gaq/11 inhibitory activity (Table 2). Particularly, GQ248 and GQ251 showed better Gaq/11 inhibitory activity than 3 at 10 μmol/L. Similarly, most of the compounds potently inhibited the growth of MP41 or 92.1 cells at low micromolar concentrations in vitro, except for GQ248 and GQ251 showed uncompetitive efficacy in combating UM cell lines in comparison...
with 3. The results revealed that releasing the restricted conformation of the carbonyl group is beneficial for increasing the Gaq/11 and tumor inhibitory efficacy.

Of interest, proline which possesses a specific pyrrolidine segment among the natural amino acids was introduced into GQ260. As depicted in Table 2, GQ260 inhibited Gaq/11 with 53.4% inhibition at 10 μmol/L, and suppressed MP41 and MP21 cells proliferation with the IC50 values of 6.7 μmol/L and 11.6 μmol/L. (-)Piperidine-2-carboxylic acid containing the piperidine fragment, which is perceived as a bioisostere of pyrrolidine, was also introduced to prepare GQ261. Compared to GQ260, the antiproliferative activity of GQ261 was retained, despite the decreased Gaq/11 inhibitory efficacy (Table 2). The results indicated that introducing the cyclic secondary amine motif into GQ260 and GQ261 could either improve the Gaq/11 inhibitory potency or enhance the antiproliferative activity of UM cells. Encouraged by these findings, and considering that the tertiary amine is potentially more metabolic and redox stable compared with the secondary amine, we thus further optimized the compounds by introducing a methyl group into the cyclic secondary amine, leading to analogs GQ262 and GQ263. To our delight, GQ262 potently inhibited Gaq/11 with 57.2 ± 1.9% suppression at 10 μmol/L, and disrupted MP41 cell proliferation with the IC50 of 5.1 ± 0.6 μmol/L (Table 2), suggesting that the cyclic tertiary amine motif is superior to secondary or primary amine.

 Inspired by the above-mentioned SARs, we combined the prevogative R substituent phenyl group and R1 substituent 1-methylpyrrolidine with four different R2 substituents (Ref. 45) which were beneficial for Gaq/11 inhibitory potency (Table 2). GQ264–GQ267 were designed and synthesized, but showed decreased inhibitory activity towards Gaq/11 and poor antitumor efficacy, compared with GQ262 (Table 2). These results indicated that the proper combination of the cyclohexylmethyl moiety with R substituent phenyl group and R1 substituent 1-methylpyrrolidine is essential for maintaining or improving the activity of compounds for combating Gaq/11 and UM cells.

Hence, we summarized the SAR information of the synthesized imidazopyrazine derivatives in Fig. 3. The phenyl substituted R is important for maintaining the inhibitory activity towards Gaq/11 and UM cells. Increasing the molecular flexibility by reducing the amide to amine generally improves the Gaq/11 inhibitory potency and the anti-UM cell ability. Introducing the cyclic tertiary motif to R1 not only acquires better Gaq/11 inhibitory efficacy, but also provides the possibility for modulating the metabolic stability. Besides, the proper combination of the R1 and R2 is essential for maintaining the Gaq/11 inhibitory efficacy and anti-UM cell ability.
Table 1  Gaq/11 inhibitory activity and antitumor activity of GQ220–GQ235.

| Compd. R | IP1 inhibition at 10 μmol/L | Antiproliferation (IC50, μmol/L) |
|----------|-----------------------------|---------------------------------|
|          |                             | MP41                           |
| GQ220    | 20.8 ± 1.1%                 | > 40                           |
| GQ221    | 20.0 ± 0.6%                 | > 40                           |
| GQ222    | 27.0 ± 5.2%                 | > 40                           |
| GQ223    | 16.6 ± 1.2%                 | > 40                           |
| GQ224    | 31.5 ± 6.0%                 | > 40                           |
| GQ225    | 28.7 ± 1.6%                 | 25.3 ± 18.8 ± 0.9              |
| GQ226    | 29.5 ± 3.0%                 | > 40                           |
| GQ227    | 18.4 ± 0.9%                 | 21.2 ± 21.6 ± 0.5              |
| GQ228    | 24.8 ± 1.5%                 | 11.0 ± 19.0 ± 0.1              |
| GQ229    | 15.8 ± 1.8%                 | > 40                           |
| GQ230    | 13.7 ± 0.6%                 | > 40                           |
| GQ231    | 20.6 ± 2.1%                 | > 40                           |
| GQ232    | 10.9 ± 0.7%                 | 19.8 ± 16.1 ± 0.1              |
| GQ233    | 22.2 ± 1.9%                 | > 40                           |
| GQ234    | 10.8 ± 1.4%                 | > 40                           |
| GQ235    | 22.3 ± 1.3%                 | > 40                           |
| 3        | 26.9 ± 3.3%                 | 11.9 ± 9.7 ± 1.0               |

*IP1 accumulation assay was utilized to characterize Gaq/11 inhibitory activity. Antitumor activity was measured utilizing CCK-8 assay. Data represent the mean ± SEM (n = 3).

2.4. Evaluation of the cytotoxicity of GQ262

The previous study revealed that part of the Gaq/11 inhibitory potency of 3 is derived from its cytotoxicity, we thus investigated the cytotoxicity of the newly designed compound GQ262 by treating the CHO-M1 cells at different concentrations, and characterized the cell viability using CCK-8 assay. As shown in Fig. 4, 3 obviously inhibited the cell proliferation at the concentrations of 10 and 20 μmol/L in 2 h, but GQ262 did not impact the cell viability at indicated concentrations in 2 h, even when the concentration up to 20 μmol/L for 24 h (Fig. 4), indicating that GQ262 has satisfactory safety towards normal cells.

2.5. Effects of GQ262 on agonist-induced BRET signals and Ca2+ release

To verify that GQ262 could trap Gaq/11 directly, we transfected AT1R, Gaq-RLuc8, unlabeled Gq1, and Gγ2-Venus in HEK293 cells which were applied to determine the bioluminescence resonance energy transfer (BRET) alteration and Ca2+ release. Pretreating HEK293-AT1R cells with 3 and GQ262 at different concentrations, followed by measuring the variable BRET signals between Gaq and Gγ3. As depicted in Fig. 5A–C, GQ262 displayed dose-dependently inhibitory efficacy on BRET signals. Also, the agonist-mediated Ca2+ release was employed to evaluate the effects of GQ262 on blocking Gaq/11. When AngII binds to AT1R, the activated AT1R initiates Gaq/11, which intertwines and activates PLCβ. As a consequence, Ca2+ release is accelerated. We pretreated 3 and GQ262 with HEK293-AT1R cells at 20 μmol/L, and assessed the agonist-stimulated Ca2+ release at different concentrations of AngII. As expected, GQ262 obviously suppressed the Ca2+ release (Fig. 5D). All these results indicated that GQ262 directly acts on Gaq/11.

2.6. GQ262 inhibits the proliferation of UM cells by targeting Gaq/11

To further validate that GQ262 suppresses UM cell proliferation directly targeting Gaq/11, we transfected the siRNA targeting GNA11 in MP41 cells and GNAQ in 92.1 cells to knock down the GNAQ/11 (Supporting Information Fig. S1). Then, we pre-treated the cells with GQ262. As depicted in Fig. 6A, GQ262 exhibited remarkable antiproliferative activity on MP41 (si#control) at 10 and 20 μmol/L, respectively. However, GQ262 could not inhibit MP41 cell proliferation (si#GNA11). Similarly, GQ262 had no inhibitory effect on proliferation of GNAQ knockdown 92.1 cells at 10 and 20 μmol/L (Fig. 6B), suggesting the antiproliferative potency of GQ262 on UM cells is achieved by blocking Gaq/11. In addition, the cellular thermal shift assay (CETSA) was employed to study whether GQ262 binds to Gaq/11 straightforwardly. As expected, the thermal denaturation temperature of Gaq/11 increased from 37 to 50 °C after the incubation of the cell lysates with GQ262 (Fig. 6C and D, Supporting Information Fig. S2), and the melting temperature was increased by 10 °C, indicating that GQ262 indeed binds to Gaq/11. Taken together, these data demonstrated that GQ262 directly binds to Gaq/11.

2.7. GQ262 induces UM cell cycle arrest and apoptosis

To investigate the mechanism of GQ262 inhibiting UM cell proliferation, we performed the cell cycle analysis utilizing flow cytometry. As depicted in Fig. 7A and B, the cellular proportion elevated from 73.8% to 78.0% and 79.4% in G0/G1 phase after separately incubating MP41 cells with GQ262 at 3 and 10 μmol/L, and the cellular proportion in S and G2/M phases was clearly decreased. In agreement with MP41 cells, 92.1 cells were incubated with GQ262 at 10 and 20 μmol/L, the cellular proportion elevated from 70.1% to 77.1% and 83.5% in G0/G1 phase (Supporting Information Fig. S3). These results demonstrated that GQ262 significantly disrupts the cell cycle of MP41 and 92.1 cells at G0/G1 phase.

To obtain further insight into the antitumor mechanism of GQ262, we conducted an apoptosis assay utilizing flow cytometer. As depicted in Fig. 7C and D, GQ262 promoted the cell apoptosis which were 11.5% (3 μmol/L) and 16.0% (10 μmol/L), while 3
Table 2  Gaq/11 inhibitory activity and antitumor activity of GQ236–GQ267.

| Compd. | R₁         | R₂ (* ) | IP₁ inhibition at 10 μmol/L | Antiproliferation (IC₅₀, μmol/L) | MP41 | 92.1 |
|--------|------------|---------|-----------------------------|----------------------------------|------|------|
| GQ236  |            |         | 48.4 ± 2.4%                 | 10.1 ± 0.2                       |      |      |
| GQ237  |            |         | 43.0 ± 3.3%                 | 4.0 ± 1.3                        |      |      |
| GQ238  |            |         | 34.4 ± 1.7%                 | 6.2 ± 0.7                        |      |      |
| GQ239  |            |         | 50.2 ± 5.2%                 | 6.0 ± 0.6                        |      |      |
| GQ240  |            |         | 22.5 ± 4.2%                 | 7.4 ± 0.3                        |      |      |
| GQ241  |            |         | 31.3 ± 9.0%                 | 5.9 ± 0.5                        |      |      |
| GQ242  |            |         | 41.0 ± 6.0%                 | 5.0 ± 0.1                        |      |      |
| GQ243  |            |         | 41.6 ± 5.8%                 | 5.7 ± 0.7                        |      |      |
| GQ244  |            |         | 45.8 ± 10.5%                | 5.6 ± 0.3                        |      |      |
| GQ245  |            |         | 46.8 ± 8.6%                 | 5.0 ± 0.3                        |      |      |
| GQ246  |            |         | 40.4 ± 7.0%                 | 14.9 ± 0.8                       |      |      |
| GQ247  |            |         | 44.5 ± 3.4%                 | 5.6 ± 0.2                        |      |      |
| GQ248  |            |         | 49.7 ± 9.5%                 | 7.9 ± 0.7                        |      |      |
| GQ249  |            |         | 44.1 ± 3.0%                 | 5.8 ± 0.6                        |      |      |
| GQ250  |            |         | 41.8 ± 2.7%                 | 6.9 ± 1.0                        |      |      |
| GQ251  |            |         | 51.2 ± 4.9%                 | 7.4 ± 0.8                        |      |      |
| GQ252  |            |         | 35.9 ± 7.3%                 | 5.2 ± 0.7                        |      |      |
| GQ253  |            |         | 32.4 ± 1.0%                 | 9.2 ± 0.6                        |      |      |
| GQ254  |            |         | 44.2 ± 0.3%                 | 8.0 ± 0.6                        |      |      |
| GQ255  |            |         | 27.7 ± 6.7%                 | > 40                             |      |      |
| GQ256  |            |         | 47.6 ± 5.0%                 | 9.0 ± 1.2                        |      |      |
| GQ257  |            |         | 33.2 ± 1.3%                 | 6.0 ± 0.3                        |      |      |

(continued on next page)
Table 2 (continued)

| Compd. | R₁ | R₂ | IP₁ inhibition at 10 μmol/L | Antiproliferation (IC₅₀, μmol/L) |
|--------|----|----|-----------------------------|---------------------------------|
|        |     |    |                             |                                 |
| GQ258  |     |    | 48.3 ± 6.5%                 | 7.9 ± 1.5                       |
| GQ259  |     |    | 36.3 ± 0.9%                 | 5.8 ± 0.6                       |
| GQ260  |     |    | 53.4 ± 7.0%                 | 6.7 ± 0.6                       |
| GQ261  |     |    | 27.0 ± 5.1%                 | 6.2 ± 0.8                       |
| GQ262  |     |    | 57.2 ± 1.9%                 | 5.1 ± 0.6                       |
| GQ263  |     |    | 38.9 ± 3.3%                 | 10.5 ± 0.7                      |
| GQ264  |     |    | 5.9 ± 1.1%                  | > 40                            |
| GQ265  |     |    | 13.5 ± 0.5%                 | > 40                            |
| GQ266  |     |    | 17.5 ± 1.1%                 | > 40                            |
| GQ267  |     |    | 8.9 ± 0.8%                  | > 40                            |
| 3      |     |    | 26.9 ± 3.3%                 | 11.9 ± 1.0                      | 9.7 ± 0.1

*IP₁ accumulation assay was utilized to characterize Gaq/11 inhibitory activity. Antitumor activity was measured utilizing CCK-8 assay. Data represent the mean ± SEM (n = 3).

Figure 3  Summary of structure—activity relationships of imidazopyrazine scaffold derivatives as Gaq/11 inhibitors.

Figure 4  Cytotoxicity of GQ262. (A) Cell viability after pre-treating with 3 and GQ262 for 2 h. (B) Cell viability after pre-treating with 3 and GQ262 for 24 h. Bar is reported as mean ± SEM (n = 3).
displayed the apoptotic value of 22.4% at 10 μmol/L. The cellular proportion augmented with the increasing concentrations of GQ262. Similarly, GQ262 effectively induced the apoptosis of 92.1 cells with the apoptotic rates of 9.34% (10 μmol/L) and 17.5% (20 μmol/L). In addition, we assessed the apoptosis related proteins, such as cysteinyl aspartate specific proteinase-7 (caspase-7), Bcl-2, and Mcl-1. As expected, GQ262 promoted the up-regulation of cleaved caspase-7 and down-regulation of Bcl-2 and Mcl-1 (Fig. 7E, Supporting Information Fig. S4). These results suggested that GQ262 dose-dependently induces the UM cell apoptosis.

2.8. GQ262 suppresses UM colony formation

To better comprehend the antitumor capacity of GQ262, the colony survival assay was conducted to investigate the inhibition of clonogenicity on UM cell lines MP41 and 92.1 (Fig. 8). Corresponding to the antiproliferative potency, GQ262 obviously blocked the
Figure 7  Cell cycle distributions and apoptotic effects of 3 and GQ262 in UM cells. (A) and (B) MP41 cell cycle distributions were measured via flow cytometer after incubating with 3 or GQ262 for 48 h. (C) and (D) Apoptotic MP41 cells were determined after incubating with 3 or GQ262 for 48 h. (E) Analysis of cleaved caspase-7, Bcl-2, and Mcl-1 levels in UM cells. Data is reported as mean ± SEM (n = 3). *P < 0.05 vs control; **P < 0.01; ****P < 0.0001.

Figure 8  Inhibition of colony formation of GQ262. (A) Photos of MP41 cell colony formation (magnification, × 40). (B) Numbers of colony formation were counted via Colony-Counter after incubating with 3 or GQ262 for 9 days. (C) Photos of 92.1 cell colony formation (magnification, × 40). (D) Numbers of colony formation were counted via Colony-Counter after incubating with 3 or GQ262 for 9 days. Data is reported as mean ± SEM (n = 3). ****P < 0.0001 vs control.
colony formation of MP41 and 92.1 cells at 1 and 3 \( \mu \text{mol/L} \). The data indicated that GQ262 has effectual antitumor activity on UM.

2.9. GQ262 suppresses UM migration and invasion

UM cells have strong metastatic characteristics, which drive the invasion towards the distant organs\(^3\). \( \text{Gaq/11} \) signaling is involved in UM cell migration, and suppressing \( \text{Gaq/11} \) could eliminate the migratory and invasive capacities of UM cells\(^3\). To verify whether GQ262 could inhibit the cell migration and invasion, Boyden chamber Transwell experiment was performed on UM cells. As depicted in Fig. 9A–D, MP41 and 92.1 cells showed aggressive migration in the absence of GQ262. To our delight, GQ262 remarkably and dose-dependently inhibited the MP41 and 92.1 migration at 3, 10, and 20 \( \mu \text{mol/L} \), compared to 3. In agreement with the effects on suppressing the migration, MP41 and 92.1 cells incubated with GQ262 exhibited poor invasion at 3, 10, and 20 \( \mu \text{mol/L} \) (Fig. 9E–H). Overall, the results revealed that GQ262 suppresses UM migration and invasion via blocking \( \text{Gaq/11} \).

2.10. Metabolic stability of GQ262

Given the effective anticancer potency of GQ262 in vitro, we evaluated the metabolic stability of GQ262 in liver microsomes of human in vitro. As depicted in Table 3, GQ262 displayed

| Compd. | Species | \( t_{1/2} \) (min)\(^a\) | \( \text{CL}_{\text{int}} \) (mL/min/kg)\(^b\) |
|--------|---------|-----------------|-----------------|
| GQ262  | Human   | 57.5            | 30.2            |

\(^a\)Half-life.  
\(^b\)Intrinsic clearance.
moderate metabolic stability with the half-time ($t_{1/2}$) of 57.5 min and the intrinsic clearance (CLint) of 30.2 mL/min/kg, indicating that GQ262 possesses moderate in vitro metabolic stability and drug-like properties, which needs to be further optimized before clinical applications.

2.11. Anti-UM efficacy of GQ262 in vivo

Encouraged by the promising in vitro antitumor activity, we conducted MP41 xenograft model to further assess the in vivo anti-UM potency of GQ262. We administrated the nude BALB/c nude mice bearing tumor with GQ262 for 21 days. The doses were 5, 15, and 30 mg/kg/day. We determined the tumor volume every two days, as well as the body weight. To our delight, tumor growth inhibition (TGI) of GQ262 was up to 106.6% at 30 mg/kg (Fig. 10A and B, Supporting Information Fig. S5). Meanwhile, GQ262 exhibited robust anticancer activity (TGI = 82.8%, 15 mg/kg), in sharp contrast to 3 (TGI = 55.3%, 15 mg/kg). GQ262 also displayed effective tumor inhibitory potency at 5 mg/kg (TGI = 55.2%, Fig. 10A and B), demonstrating that GQ262 is highly potent for combating MP41 xenograft model.

Importantly, body weight of the mice did not decline (Fig. 10D) and we did not observe manifest side effects during and after the treatment (Fig. 10E, Supporting Information Fig. S6). All these results strongly supported our hypothesis that directly inhibiting constitutively activated Gaq/11 is a powerful and effective approach for treating UM, other than inhibiting a specific node in the downstream signaling pathways.

2.12. GQ262 modulates ERK and YAP by targeting Gaq/11

ERK is a canonical effector in Gaq/11-PLCβ signaling pathway, and participates in complex process of cell mitosis after phosphorylation\(^{17-19}\). Inhibiting Gaq/11 could block the phosphorylation of ERK, which then suppresses the growth of UM. To verify the effects of GQ262 on suppressing the ERK phosphorylation, we evaluated the expression level of phosphorylated ERK in MP41 xenograft tumor tissues (Fig. 11, Supporting Information Fig. S7). As expected, GQ262 indeed inhibited the phosphorylated ERK in tumor tissues at the testing dose.

Yes-associated protein (YAP) is another primary mediator for tumorigenesis, and contributes to the development of UM\(^{22}\). Dephosphorylation of YAP is initiated by the activated Gaq/11, which promotes the proliferation of UM. Thereby, the

![Figure 10](image1.png) Anti-UM efficacy of GQ262 in vivo. Mice were administered with 3 and GQ262 via intraperitoneal injection (ip) for 21 days ($n = 6$). (A) Tumor volume. (B) Tumor weight. (C) Photo of tumor tissue. (D) Body weight. (E) H&E staining. *$P < 0.05$ vs vehicle; ***$P < 0.001$; ****$P < 0.0001$.

![Figure 11](image2.png) Effects of 3 and GQ262 on modulating the Gaq/11 downstream signaling effectors in MP41 xenograft ($n = 6$). Expression of targeted proteins (ERK, p-ERK, YAP, and p-YAP) was analyzed utilizing Western blot.

| Parameter | Route of dosing |
|-----------|----------------|
| Dose (mg/kg) | 5 15 |
| $t_{1/2}$ (h) | 1.8 ± 0.2 2.4 ± 0.7 |
| $T_{max}$ (h) | 0.08 ± 0.00 0.5 ± 0.4 |
| $C_{max}$ (ng/mL) | 2471 ± 192 1036 ± 267 |
| AUC$_{0-\infty}$ (h·ng/mL) | 1625 ± 70 2899 ± 358 |
| MRT$_{0-\infty}$ (h) | 1.1 ± 0.1 3.1 ± 0.7 |
| $V_{ss}$ (L/kg) | 3.9 ± 0.4 — |
| $CL$ (mL/min/kg) | 50.2 ± 2.1 — |
| $F$ (%) | — 59.5 |
phosphorylated YAP expression was determined in MP41 xenograft tumor tissues (Fig. 11). As expected, GQ262 increased the accumulation of phosphorylated YAP at the testing dose.

Altogether, these results unveiled that GQ262 effectively inhibits the downstream signaling networks of Gaq/11 by targeting Gaq/11 in UM.

2.13. Pharmacokinetic (PK) studies of GQ262

To better comprehend the druggability of GQ262, the male ICR mice were employed to assess the PK properties. The dose of intravenous injection (iv) was 5 mg/kg, and the dose of oral administration (po) was 15 mg/kg. In comparison to 4 with short t₁/₂ (1.2 h)³⁵, GQ262 showed increased elimination t₁/₂ with the value of 1.8 h (Table 4). As shown in Table 4, GQ262 attained the AUCₘₚ of 1.8 h (Table 4). As shown in Table 4, GQ262 attained the AUCₘₚ of 1.8 h (Table 4). As shown in Table 4, GQ262 attained the AUCₘₚ of 1.8 h (Table 4). As shown in Table 4, GQ262 attained the AUCₘₚ of 1.8 h (Table 4). As shown in Table 4, GQ262 attained the AUCₘₚ of 1.8 h (Table 4).

3. Conclusions

In summary, we developed a novel Gaq/11 inhibitor GQ262 with high efficacy, good security, and augmented PK. GQ262 exhibited outstanding potency in combating UM both in vitro and in vivo, and we also verified the direct interaction between GQ262 and Gaq/11. Discovery of GQ262 provides a new and effective anti-UM drug candidate via directly targeting Gaq/11, however drug-like properties including the Gaq/11 inhibitory potency, metabolic stability, selectivity among normal cells and UM cells, and cardiotoxicity are needed to be further optimized, these works are currently under way in our lab.

4. Experimental

4.1. Chemistry

All reagents used in this manuscript are commercially available. ¹H and ¹³C NMR spectra were utilized to characterize chemical structures with a Bruker AVANCE at 400 and 100 MHz. High-resolution mass spectrometer was recorded utilizing Shimadzu LCMS-IT-TOF. Chemical reactions were monitored by utilizing TLC with 0.2 mm silica gel plates (HSGF254, Huanghai). All compounds are >95% pure by reverse-phase analytical HPLC. See supporting information for HPLC conditions, detailed chemical data, and ¹H and ¹³C NMR spectra.

4.2. Cell culture

The CHO-M₁ cells were given to us by Xinmiao Liang (Dalian Institute of Chemical Physics, Chinese Academy of Sciences) as a generous gift. We cultured the CHO-M₁ cells in F12K media (Gibco), G418 (0.25 mg/mL, Beyotime), and FBS (10% (v/v), Gibco). MP41 cells, one of UM cell lines, were given to us by Jingxuan Pan (Zhongshan Ophthalmic Center, Sun Yat-sen University) as a generous gift. 92.1 cells, another UM cell line, were bought from FuHeng BioLogy Co., Ltd. (Shanghai). We cultured MP41 and 92.1 cells in RPMI-1640 (Gibco), which was added to fetal bovine serum (10% (v/v), Gibco). These three cell lines were maintained in 95% air, 5% CO₂ and 37 °C.

4.3. IP₁ assay

CHO-M₁ cells were collected and seeded in 384-well plates. The cell density reached 2 × 10⁴ cells/well. We added test compounds to pre-treat the cells at 37 °C. After incubating for 1 h, carbachol (Sigma) containing LiCl (200 mmol/L) was prepared and added, which achieved the final concentration to 9 mmol/L. After incubating for 1 h, we added the detection solution (2.5% anti-IP₁ cryptate Tb conjugate (Cisbio) + IP₁ conjugate and lysis buffer (Cisbio) + 2.5% d-myco-IP₁-d2 conjugate (Cisbio) to the plates at room temperature. After incubating for 1 h, the plates were read on an HTRF® compatible reader.

4.4. Cell proliferation inhibition assay

MP41 and 92.1 cells were collected and resuspended in RPMI-1640 (3 × 10³ cells/mL). Then we seeded the cells into 96-well plates and placed the plates overnight. After culturing, we added indicated concentrations of compounds to the plates. After incubating for 72 h, we added CCK-8 (10 µL/well). Then, we placed the plates an incubator for 2–4 h and determined the absorption at 450 nm utilizing a microplate reader. We calculated the IC₅₀ values by utilizing GraphPad Prism 8.0 software. IC₅₀ values were shown as mean ± SEM.

4.5. BRET measurements

HEK293 cells, which expressed AT₁ receptor along with Gaq/11, unlabeled Gβ1, and G₂−Venus, were transfected transiently utilizing the standard protocol. In accordance with previously reported procedures, we collected and seeded the cells into 96-well plates after transfecting for 24 h. The plates were placed in the incubator overnight. Then, 3 and GQ262 were added to pre-treat the cells. After incubating for 1 h, agonist AngII was added, followed by we added coelenterazine (luciferase substrate). Flex Station 3 (Moleculardevices) was utilized to determine the BRET signals.

4.6. Intracellular calcium release measurements

HEK293 cells, which overexpressed AT₁R, were utilized to measure calcium release. In accordance with previously reported procedures, 1 mmol/L Fluo-4 AM, a calcium-sensitive molecular probe, were loaded into the cells at 37 °C. After incubating for 1 h, we added 3 or GQ262 to plates to pre-treat the cells. After treating for 0.5 h, different concentrations of AngII were added. Flex Station 3 (Moleculardevices) was utilized to determine the excitation/emission (485 nm/525 nm).

4.7. Rescue assay

We collected and seeded MP41 cells into six-well plates, and placed the plates in the incubator overnight. Then, we utilized the DharmamFECT (Dharmacon, USA) to transfect siRNA targeting GNA11 (AGAUGAUGUUCUCCAGUCAGAAAGG) or control (AGAAUGAUGUUCUGACCCUGAGG) in MP41 cells and GNAQ (GCACAAUUAGUUCGAGAAGU) or control
We collected and seeded MP41 cells into six-well plates and placed the plates in the incubator overnight. Then, GQ262 was added to pre-treat the cells. After incubating for 1 h, we collected the cells and conducted CETSA assay. Then, the cells were divided into 4 parts equally. We heated each sample under different temperature (37, 40, 45, and 50 °C) for 3 min. After cooling at 4 °C, the cells were left to snap frozen at liquid nitrogen for 3 min, then unfrozen at 55 °C, and the process repeated one more time. Subsequently, we centrifuged cell lysates at 4 °C (20,000 x g). After centrifuging for 15 min, levels of Gaq/11 were measured by western blot.

4.9. Cell cycle and apoptosis analysis

We collected and seeded MP41 cells into six-well plates and placed the plates in the incubator overnight. The cell density reached 3 x 10^5 cells/well. Then, 3 and GQ262 were added to pre-treat the cells for 48 h. For cell cycle, we washed and fixed the cells at 4 °C by utilizing 70% ethanol. After fixing for 12 h, we stained the cells at 37 °C by utilizing RNase (100 µg/mL) and PI (50 µg/mL) for 0.5 h. For apoptosis, we washed and collected the cells, which were then stained by utilizing 5 µL Annexin V-FITC. After staining for 15 min, we then stained the cells by utilizing 10 µL PI for 5 min. Flow cytometer was utilized to assess the samples (Beckman Coulter, USA).

4.10. Clonogenic assay

We collected and seeded MP41 cells into 12-well plates and placed the plates in the incubator overnight. The cell density reached 4000 cells/well. Next, 3 and GQ262 were added to treat the cells. RPMI-1640 and test compounds were replaced every three days. After incubating for 9 days, we fixed the cells utilizing 4% paraformaldehyde. After fixing for 15 min, crystal violet (Solarbio, China) was utilized to stain the clonogenic cells for 4% paraformaldehyde. After fixing for 15 min, crystal violet (Solarbio, China) was utilized to stain the clonogenic cells for 3 min. We then stained the cells by utilizing 5 µL Annexin V-FITC. After staining for 15 min, we then stained the cells by utilizing 10 µL PI for 5 min. Flow cytometer was utilized to assess the samples (Beckman Coulter, USA).

4.11. Migration and invasion assay

We collected and seeded MP41 cells into 24-well Transwell upper chambers (1 x 10^5 cells/well). The lower chamber was added RPMI-1640 containing 20% FBS. The plates were placed overnight in an incubator. Then, 3 and GQ262 were added to pre-treat the cells. After incubating for 48 h, we discarded the cells which situated in the upper chamber, then we stained the cells which situated in the lower chamber utilizing crystal violet (Solarbio, China). After staining for 0.5 h, migrative and invasive cells were observed and counted utilizing a microscope (magnification x 40 and x 100, Nikon).

4.12. Human liver microsome stability assay

We prepared potassium phosphate buffer (100 mmol/L, pH 7.4) containing 0.5 mg/mL liver microsome and 5 mmol/L MgCl2 and added to 96-well plates. Next, GQ262 was incubated with the human liver microsome buffer at the concentration of 1 µmol/L. After incubating for 5 min (37 °C), we added 1 µmol/L NADPH to the wells. 150 µL acetonitrile, which included internal standard, was added to quench the reactions at 0, 5, 15, 30, and 45 min. We shook the plates for 10 min (600 rpm). After shaking, the collected samples were centrifuged for 15 min (6000 rpm) and analyzed utilizing LC–MS/MS.

4.13. Western blot

We lysed the cells or tumor tissues utilizing RIPA buffer (Beyotime, China) containing phosphatase inhibitors (Bimake, USA) and protease inhibitors (Beyotime, China). In accordance with previously reported procedures45, we centrifuged the lysates at 4 °C and 15,000 rpm. After centrifuging for 15 min, we separated the supernatants and assessed the protein concentration utilizing a BCA assay. 8%–12% SDS-PAGE gels were utilized to separate the targeted proteins. Next, we transferred target proteins to PVDF membranes (Millipore, USA), which were then blocked by utilizing 5% BSA. After 60 min, we incubated the primary antibodies with the membranes overnight at 4 °C. The primary antibodies contain GAPDH (CST 5174), cleaved caspase-7 (CST 9491), Bel-2 (CST 3498), Mcl-1 (CST 4572), total YAP (CST 14074), phospho-YAPSer127 (CST 13008), total ERK1/2 (CST 4695), and phospho-ERK1/2Thr202/Tyr204 (CST 4370). After incubating with secondary antibodies, we measured the targeted proteins utilizing an enhanced chemiluminescence.

4.14. MP41 xenograft model

Nude BALB/c nu/nu mice (18–22 g, 6–8 weeks) were brought from Gempharmatech Co, Ltd. (Nanjing, SCXK(Guangdong) 2021-0029). The Research Ethics Committee of Sun Yat-sen University approved the animal procedures (Approval No. SYSU-IACUC-2021-000858). In accordance with previously reported procedures45, the mice with MP41 xenograft tumors were grouped randomly (n = 6/group) and administrated for 21 consecutive days with vehicle, 3 (15 mg/kg/day), or GQ262 (5, 15, or 30 mg/kg/day). The route of administration was intraperitoneal injection (ip), and we monitored the body weight and tumor size every 2 days. On Day 22, we gained the tumor blocks. GraphPad Prism 8.0 software was utilized to analyze the data.

4.15. Pharmacokinetic studies

ICR mice were treated with GQ262 to study the pharmacokinetics. The dose of iv was 5 mg/kg, or the dose of po was 15 mg/kg. After administration, we collected 30 µL blood samples at 0, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h. Then we centrifuged the samples at 6800 x g, 2–8 °C. After centrifuging for 6 min, the samples were kept at −80 °C and measured by LC–MS/MS. We calculated the pharmacokinetic parameters utilizing WinNonlin, version 7.0 (Pharsight, USA) and showed the data as mean ± SEM.
4.16. Statistical analysis

Each experiment was carried out in triplicate and repeated at least twice except for animal experiments. Data were shown as mean ± SEM. Significance between controls and treatments was assessed by Student’s test utilizing GraphPad Prism 8.0 software. Animal experiments were analyzed utilizing the one-way ANOVA. The significant differences were considered at the level of *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Acknowledgments

The authors acknowledge financial support by National Natural Science Foundation of China (No. 22077144 and 81973359), Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2018B030306017, China), Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery (2019B030301005, China), Key Reasearch and Development Program of Guangdong Province (2020B1111110003, China), Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017B011Y093, China), National Engineering and Technology Research Center for New Drug Druggability Evaluation (Seed Program of Guangdong Province, 2017B090903004) and Jilin Province Science and Technology Development Project (20200404105YY).

Author contributions

Xiao-Feng Xiong and Xiaolei Zhang conceived the project. Xiao-Feng Xiong and Yang Ge designed the synthesis, Yang Ge and Jun-Jie Deng performed the synthesis. Yang Ge, Jianzheng Zhu, Lu Liu, Shumin Ouyang, and Zhendong Song performed biological evaluation. Yang Ge, Xiao-Feng Xiong, and Xiaolei Zhang wrote the manuscript, with input from all the authors. All authors have approved the final article.

Conflicts of interest

The authors declare no competing financial interest.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2022.04.016.

References

1. Gilman AG. G proteins: transducers of receptor-generated signals. *Ann Rev Biochem* 1987;56:615–49.
2. Malbon CC. G proteins in development. *Nat Rev Mol Cell Biol* 2005;6:689–701.
3. Downes GB, Gautam N. The G protein subunit gene families. *Genomics* 1999;62:544–52.
4. Oldham WM, Hamn HE. Heterotrimeric G protein activation by G-protein-coupled receptors. *Nat Rev Mol Cell Biol* 2008;9:60–71.
5. Campbell AP, Smrcka AV. Targeting G protein-coupled receptor signalling by blocking G proteins. *Nat Rev Drug Discov* 2018;17:789–803.
6. Simon MI, Straathorn MP, Gautam N. Diversity of G proteins in signal transduction. *Science* 1991;252:802–8.
7. Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. *Anna Rev Pharmacol Toxicol* 1996;36:461–80.
8. Katada T, Bokoch GM, Northup JK, Ui M, Gilman AG. The inhibitory guanine nucleotide-binding regulatory component of adenylyl cyclase. Properties and function of the purified protein. *J Biol Chem* 1984;259:3568–77.
9. Smrcka AV, Hepler JR, Brown KO, Sternweis PC. Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq. *Science* 1991;251:804–7.
10. Lee CH, Park D, Wu D, Rhee SG, Simon MI. Members of the Gq alpha subunit gene family activate phospholipase C beta isoforms. *J Biol Chem* 1992;267:16044–7.
11. Taylor SJ, Chae HZ, Rhee SG, Exton JH. Activation of the β1 isozyme of phospholipase C by α subunits of the Gq class of G proteins. *Nature* 1991;350:516–8.
12. Kozasa T, Jiang X, Hart MI, Sternweis PM, Singer WD, Gilman AG, et al. p15 RhoGEF, a GTPase activating protein for Gα12 and Gα13. *Science* 1998;280:2109–11.
13. Hart MI, Jiang X, Kozasa T, Roscoe W, Singer WD, Gilman AG, et al. Direct stimulation of the guanine nucleotide exchange activity of p15 RhoGEF by Gα13. *Science* 1998;280:2112–4.
14. Strathmann MP, Simon MI. Gα12 and Gα13 subunits define a fourth class of G protein α subunits. *Proc Natl Acad Sci USA* 1991;88:5582–6.
15. Li J, Ge Y, Huang JX, Strenguard K, Zhang X, Xiong XF. Heterotrimeric G proteins as therapeutic targets in drug discovery. *J Med Chem* 2020;63:5013–30.
16. Morris AJ, Malbon CC. Physiological regulation of G protein-linked signaling. *Physiol Rev* 1999;79:1373–430.
17. Weinstein LS, Chen M, Xie T, Liu J. Genetic diseases associated with heterotrimeric G proteins. *Trends Pharmacol Sci* 2006;27:256–60.
18. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. Direct stimulation of the guanine nucleotide exchange activity of Gα13 by the activated α subunits of the Gq class of G proteins. *Nature* 1991;350:516–8.
19. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. *N Engl J Med* 2010;363:2191–9.
20. Kan Z, Jasswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. *Nature* 2010;466:869–73.
21. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. *N Engl J Med* 1991;325:1688–95.
22. Smrcka AV. Molecular targeting of Gα12 and Gα13 family α subunits: a potential approach for cancer therapeutics. *Trends Pharmacol Sci* 2013;34:290–8.
23. Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. *Nat Rev Dis Prim* 2020;6:24.
24. Smit KN, Jager MJ, de Klein A, Kili E. Uveal melanoma: towards a molecular understanding. *Prog Retin Eye Res* 2020;75:100800.
25. Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivela TT. Metastatic uveal melanoma: the final frontier. *Prog Retin Eye Res* 2020;75:100800.
26. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* 2009;457:599–602.
27. Shoushtari AN, Carvalj RD, GNAQ and GNA11 mutations in uveal melanoma. *Melanoma Res* 2014;24:525–34.
30. Urtatiz O, Van Raamsdonk CD. Gnaq and Gna11 in the endothelin signaling pathway and melanoma. *Front Genet* 2016;7:59.
31. Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. *Br J Cancer* 2017;117:884–7.
32. Kim CY, Kim DW, Kim K, Curry J, Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic mucosal melanoma. *BMC Cancer* 2014;14:516.
33. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. *Cancer* 2018;124:4080–9.
34. Maziarz M, Leyme A, Marivin A, Luebbers A, Patel PP, Chen Z, et al. Atypical activation of the G protein Ga by the oncogenic mutation Q209P. *J Biol Chem* 2018;293:19586–99.
35. Annala S, Feng X, Shihar N, Eryilmaz F, Patt J, Yang J, et al. Direct targeting of Gaq and Gai11 oncoproteins in cancer cells. *Sci Signal* 2019;12:eaau5948.
36. Larribère L, Utikal J. Update on GNA alterations in cancer: implications for uveal melanoma treatment. *Cancers* 2020;12:1524.
37. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. *Am J Ophthalmol* 2004;137:683–96.
38. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. *Ophthalmology* 2011;118:1881–5.
39. Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted therapy of uveal melanoma: recent failures and new perspectives. *Cancers* 2019;11:846.
40. Liu X, Yin M, Dong J, Mao G, Min W, Kuang Z, et al. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR. *Acta Pharm Sin B* 2021;11:3134–49.
41. Vivet-Noguer R, Tarin M, Roman-Roman S, Alsafadi S. Emerging therapeutic opportunities based on current knowledge of uveal melanoma biology. *Cancers* 2019;11:1019.
42. Xiong XF, Zhang H, Underwood CR, Harpsøe K, Gardella TJ, Wöldike MF, et al. Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors. *Nat Chem* 2016;8:1035–41.
43. Fujioka M, Koda S, Morimoto Y, Biemann KS. Structure of FR900359, a cyclic depsipeptide from Ardisia crenata sims. *J Org Chem* 1988;53:2820–5.
44. Ayoub MA, Damian M, Gespach C, Ferrandis E, Lavergne O, De Wever O, et al. Inhibition of heterotrimeric G protein signaling by a small molecule acting on Ga subunit. *J Biol Chem* 2009;284:29136–45.
45. Ge Y, Shi S, Deng JJ, Chen XP, Song Z, Liu L, et al. Design, synthesis, and evaluation of small molecule Gaq/11 protein inhibitors for the treatment of uveal melanoma. *J Med Chem* 2021;64:3131–52.
46. Nishimura A, Kitano K, Takasaki J, Taniguchi M, Mizuno N, Tago K, et al. Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. *Proc Natl Acad Sci U S A* 2010;107:13666–71.
47. Schrage R, Schmitz AL, Gaffal E, Annala S, Kehraus S, Wenzel D, et al. The experimental power of FR900359 to study Gq-regulated biological processes. *Nat Commun* 2015;6:10156.
48. Schmitz AL, Schrage R, Gaffal E, Charpentier TH, Wiest J, Hillensperger G, et al. A cell-permeable inhibitor to trap Gαq proteins in the empty pocket conformation. *Chem Biol* 2014;21:890–902.